BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Inclinix, Inc. Secures $10 Million in Expansion Funding


1/10/2008 11:46:30 AM

Wilmington, N.C. —January 7, 2008— Inclinix, Inc., an enrollment contract research that the company has closed $10 million in expansion funding from Frontier Capital. Frontier is a private equity firm providing growth equity to business services companies.

Inclinix accelerates the clinical trials of new drugs by delivering qualified doctors and patients for enrollment. The company will use the investment to fund further enhancement of its proprietary enrollment processes and technologies. Inclinix will also add sales, marketing, and service delivery resources and expand its corporate facilities. “We are excited about this investment, which will help us continue the tremendous growth of our company,” said J. Tobin Geatz, president and CEO. “Inclinix has grown 40 percent annually the past three years and sought capital to better serve our customers and accelerate our expansion. We will continue to provide industry-leading enrollment services and technologies to some of the world’s largest pharmaceutical, biopharmaceutical and medical device companies on a global basis.”

Michael Ramich, partner at Frontier Capital, said, “After watching Inclinix’s progress and growth over the past few years, we have been significantly impressed. They have proven expertise in delivering enrollment solutions to the leading sponsors conducting clinical research today. We are pleased to make this commitment and look forward to supporting Inclinix’s continued growth and development as a leading CRO.”

About Inclinix Founded in 1999, Inclinix, Inc., is the industry’s Enrollment CRO. Inclinix’s IQMÔ Intelligent Enrollment process uses technology to amplify traditional services and is proven to accelerate trials for pharmaceutical, biotechnology and medical-device organizations. In addition to its clinical research-related offerings, Inclinix provides strategic medical marketing communications and adherence services to the healthcare industry. For more information on Inclinix, visit www.inclinix.com


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->